Why the study?
Does the addition of endothelin receptor antagonists to RAAS inhibitors reduce proteinuria and improve renal outcomes in patients with chronic kidney disease?
Population
Patients with chronic kidney disease (CKD), particularly diabetic nephropathy
Comparison
Dual inhibition of the renin-angiotensin-aldoster… vs RAAS inhibitors alone (monotherapy)
Design
Review
Authors
Loading...
Supports ERA addition for residual proteinuria in diabetic nephropathy; leaves open long-term nephroprotection and safety.
Does the addition of endothelin receptor antagonists to RAAS inhibitors reduce proteinuria and improve renal outcomes in patients with chronic kidney disease?
Dual inhibition of RAAS and endothelin-1 shows promise in reducing residual proteinuria in CKD, but long-term trials are needed to confirm hard clinical nephroprotection and assess the risk of fluid overload.
Komers et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: